Aim: to study links between morphological glomerular kidney lesion parameters and serum cystatin C (CysC) in patients with chronic glomerulonephritis (CGN) with saved renal function, and to assess therapeutic correction of identified changes using ACE inhibitor ramipril. Methods: eighty one patients with CGN were enrolled in the study. Blood samples of the biomarker were collected. The diagnosis of "chronic glomerulonephritis" was verified on the basis of clinical, laboratory and morphological data. Patients were divided into 2 clinical groups: patients with CGN and arterial hypertension (AH) and without AH. We used data of renal biopsies to analyze the indicators of glomerular kidney lesion in patients with CGN. The level of serum CysC was measured using ELISA kits. Treatment of patients was carried out over 24 weeks using the ACE inhibitor ramipril. The average daily dose of ramipril for the entire treatment period for patients with AH was 12.8±5.6 mg, patients of the second group-
Introduction
Chronic glomerulonephritis (CGN) is a social problem because of morbidity and early mortality of mainly young patients [2] . The rate of this disease in nosological structure of patients receiving renal replacement therapy is up to 45% [1] . In addition, CGN is one of the main reasons for secondary arterial hypertension (AH) development [3, 4] . Glomerulosclerosis is the basis for chronic kidney failure evolution [1, 2, 4] . That is why it is important for patients with CGN to diagnose glomerular kidney lesion on time. Renal biopsy remains one of the main diagnostic methods in modern nephrology. It gives us information about the nature of pathological changes, we can predict the effectiveness of therapy, estimate risk of adverse outcome and rate of renal function loss. Nowadays there is an increased interest in biological markers that allow suggesting the character of kidney morphological changes and monitor the effectiveness of treatment [1, [3] [4] [5] [6] [7] . To a certain extent of cystatin C (CysC) is a marker, which makes it possible to determine glomerular lesion [4] . Implementation of the marker in routine clinical practice is limited up to the present because of insufficient evidence base; hence the lack of information on strategies to influence on it and justify feasibility of studies in this area.
Currently angiotensin-converting enzyme (ACE) inhibitors for efficacy and safety meet the "ideal" of antihypertensive agents [8] . Ramipril is a long acting lipophilic drug with two major ways of excretion. It not only effectively normalizes blood pressure (BP), but also improve the prognosis of patients with nephropathy due to lower the tone of efferent arterioles and intraglomerular pressure that inhibits proliferation of mesangial cells, decreases synthesis of mesangial matrix components and level of proteinuria [8, 9] . However, ACE inhibitor therapy is used too late because the clinical signs of renal failure show up only after losing more than 50 % of nephrons. Therefore, the main factor for the prognosis of patients with CGN is a timely diagnostics and early treatment of glomerular kidney lesion [10] . The aim of the study was to evaluate a link between Assessment of nephroprotective action of angiotensin-converting enzyme 9 morphological glomerular kidney lesion parameters and serum CysC in patients with CGN with saved renal function, and to assess therapeutic correction of identified changes using ACE inhibitor ramipril.
Design and Methods
Eighty one patients with CGN were enrolled in the study (average age was 37.6±1.3 years). The diagnosis of "chronic glomerulonephritis" was verified on the basis of clinical, laboratory and morphological data. Patients were divided into 2 clinical groups: patients with CGN and AH and without AH. The first group included 49 patients with CGN and AH, 34 (69%) men, 15 (31%) women, who had an average age of 36.3±2.3 years, disease duration 87.1±9.8 months. Nephrotic syndrome with proteinuria (PU) above 3 g/l was observed in 8% of patients. Urinary syndrome with low PU and different severity of erythrocyturia was detected in 86% of patients, PU above 1 g/l -in 6%. The average daily level of PU was 1.4±0.1 g/day. The second clinical group -32 patients with CGN without AH, there were 20 (63%) men and 12 (37%) women, average age was 38.7±7.5 years, disease duration -47.1±6.8 months. Urinary syndrome was manifested by low PU and different severity of erythrocyturia. The average daily level of PU was 0.41±0.04 g/day. In 66% of patients lab picture was defined as remission. The control group consisted of 20 healthy individuals, there were 10 (50%) men and 10 (50%) women with average age 40.1±2.4 years. They were examined to clarify the standards of level markers.
Treatment of patients was carried out over 24 weeks using the ACE inhibitor ramipril. The starting dose for patients with CGN and AH was 10 mg once daily, for patients with CGN without AH -2.5 mg 1 time per day. All patients did not receive permanent antihypertensive therapy or it was canceled 48 hours prior to inclusion in the study. If there was no blood pressure reduction of at least 10% compared with baseline during first two weeks of treatment, the study protocol anticipated an increase in the dose of drug to 20 mg per day. The average daily dose of ramipril for the entire treatment period for patients with AH was 12.8±5.6 mg. Patients of the second group -without AH, were treated with ramipril at a dose of 2.5 mg without further titration.
We used the following morphological parametres to assess glomerular kidney lesion: mesangial cellularity score, expansion of mesangial matrix (MM), presence of glomerulosclerosis, fibrocellular crescents, endocapillary hypercellularity, thickening of peripheral capillary loops and glomerular basement membrane [2] .
The level of serum cysC was determined using ELISA kits (BioVendor, Czech Republic), all rates were obtained automatically and calculated in ng/ml.
Statistics
All statistical analyses were performed in SPSS for Windows v. 7 17.0 (SPSS Inc., USA). The study data was presented as mean (M) and ± standard deviation (SD), serum levels of markers -as median and 25%-75% confidence interval (CI). We evaluated the diagnostic accuracy of renal morphological changes on the level of serum cysC compared to kidney biopsy by calculating operating performance tests, which include: diagnostic sensitivity, diagnostic specificity and diagnostic efficiency. Diagnostic efficiency (DE) is defined as the arithmetic mean of the diagnostic sensitivity (Se) and diagnostic specificity (Sp) by the formula: DE=(Se+Sp) / 2. A calculated difference of P<0.05 was considered significant.
Results
The results of the basic laboratory parameters of studied patients are presented in table 1. According to the results of renal microscopy 88% patients had mesangial proliferative glomerulonephritis, 7% -membranous nephropathy, 5% -membranous proliferative glomerulonephritis.
We investigated serum levels of CysC in patients with CGN and control group. Results are presented in table 2. We determined serum CysC as a marker of glomerular kidney lesion, so a rank correlation analysis between the serum levels of CysC and indicators of glomerular kidney lesion in patients with CGN was conducted. Results are presented in table 3. Table 3 We found out that level of serum cysC directly correlated with thickening of glomerular basement membrane (r = 0.30, p < 0.05), peripheral capillary loops (r = 0.21, p < 0.05), mesangial cellularity score (r = 0.32, p < 0.05), presence of endocapillary hypercellularity (r = 0.37, p < 0.05) and fibrocellular crescents (r = 0.43, p < 0.05), glomerulosclerosis (r = 0.85, p < 0.05).
We evaluated diagnostic accuracy of glomerulosclerosis with serum cysC by calculating operating tests, such as diagnostic sensitivity, specificity and efficiency. Diagnostics of glomerulosclerosis was carried out by two methods in 81 patients with CGN: the first method -renal biopsy, which is considered to be the diagnostic standard, the second -definition of serum cysC. Results are presented in table 4. According to the table 4 we defined diagnostic sensitivity for glomerulosclerosis determining by the serum cysC, which was 93.1%, diagnostic specificity -100% diagnostic efficiency -96.55%. So glomerulosclerosis diagnostics by using serum cysC is a highly sensitive and specific method, with the efficiency up to 96.55%.
Dynamics of average values of the basic laboratory parameters in patients with CGN before and after ramipril treatment is presented in table 6 .
We observed decrease in such indicators as blood creatinine and PU to 8.2% and 69% respectively (p < 0.05) in patients with CGN and AH. In the group of patients with CGN without AH there was a reduction of PU and blood creatinine to 92% and 9.9% respectively (p < 0.05). Besides, we statistically confirmed that treatment with ramipril in patients with CGN led to lower average of the glomerular kidney lesion marker levels. Dynamics of serum CysC changes before and after ramipril treatment is presented 13   in table 7 . We observed decrease in serum CysC up to 20.3% (p < 0.05) in patients with CGN and AH and up to 13.0% in the group of patients with CGN without AH. Thus, levels of glomerular kidney lesion markers reduced under the influence of 24-week ramipril treatment that confirmed nephroprotective effect of the drug. 
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Conclusions
There is a direct correlation between serum CysC and glomerulosclerosis (r = 0.85, p < 0.05) in patients with CGN. Serum CysC is the most sensitive marker of glomerular kidney lesion with diagnostic efficiency up to 97%. The 24-week treatment with ACE inhibitor ramipril in patients with CGN with and without AH reduced levels of glomerular kidney lesion markers that confirmed nephroprotective effect of the drug.
